Subtype
Cervical Neoplasm
CI-CAN-00004801Explore in graph →
Non-malignant573 active trials4 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004801Explore in graph →
Clinical trials
2,386 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06256224 | Toripalimab Combined With Definitive CCRT for LACC Patients | recruiting | N/A | 150 | Ruijin HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05817214 | Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer | recruiting | Phase 2 | 35 | Zhongnan HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05027776 |
| recruiting |
| Phase 3 |
| 1,348 |
| Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY |
| 1 |
| Apr 17, 2024 |
| clinicaltrials |
| NCT05371353 | Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | recruiting | — | 600 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06358053 | CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers | not yet recruiting | Phase 1 | 24 | Corregene Biotechnology Co., LtdINDUSTRY | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06333821 | A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma | not yet recruiting | Phase 3 | 460 | Biotech Pharmaceutical Co., Ltd.OTHER | 0 | Mar 27, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06155396 | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 116 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06284031 | Cervical Cancer Brachytherapy With Interstitial Needles in 3 Fractions | recruiting | N/A | 56 | National University Hospital, SingaporeOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06273553 | A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 | not yet recruiting | Phase 1 / Phase 2 | 39 | RinuaGene Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 22, 2024 | clinicaltrials |
| NCT06254729 | Clinical Study on the Evaluation of the Efficacy of Cervical Cancer(EECC) | not yet recruiting | — | 4,000 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Feb 12, 2024 | clinicaltrials |
| NCT06230549 | Adaptive Radiotherapy in Patients With Gynecological Tumors(ProART) | recruiting | N/A | 30 | University Hospital, EssenOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06251388 | A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer | recruiting | Phase 2 | 50 | West China Second University HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06209294 | Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery | recruiting | Phase 2 | 30 | Xiaohua WuOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT06197126 | MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy | not yet recruiting | — | 200 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05492123 | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | recruiting | Phase 2 | 112 | Hospital Israelita Albert EinsteinOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05173272 | Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer | recruiting | Phase 3 | 286 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05613283 | Primary Cervical Cancer Screening by Self-sampling HPV Test(PREVENT) | active not recruiting | — | 17,875 | Peking University People's HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04475354 | Distress In CErvical Cancer Patients and Partners(DICE) | recruiting | — | 832 | Comprehensive Cancer Centre The NetherlandsOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06150222 | Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study(Retro-COSMOS) | not yet recruiting | — | 350 | Erasmus Medical CenterOTHER | 0 | Dec 1, 2023 | clinicaltrials |
| NCT06128460 | Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. | not yet recruiting | Phase 2 | 24 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT06149767 | Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer | not yet recruiting | Phase 2 | 26 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 29, 2023 | clinicaltrials |
| NCT06118463 | Study on AUNIP as a Novel Tumor Marker for Cervical Cancer | not yet recruiting | — | 300 | Lin YuanOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT06101966 | A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy | not yet recruiting | — | 500 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05406856 | PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer(PROTECT) | recruiting | N/A | 30 | Leiden University Medical CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT05749887 | The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer. | recruiting | N/A | 188 | Chongqing University Cancer HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06062589 | AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer | not yet recruiting | — | 18 | Peking University Third HospitalOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT06055738 | Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC | recruiting | Phase 2 | 20 | Tang-Du HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06039982 | A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer | not yet recruiting | — | 100 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06039891 | Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer | not yet recruiting | Phase 2 | 55 | Peking Union Medical College HospitalOTHER | 0 | Sep 15, 2023 | clinicaltrials |
| NCT06028724 | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)(POPCORN) | recruiting | — | 782 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05405270 | Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment(PRedICT-TOPIC) | recruiting | — | 410 | Catharina Ziekenhuis EindhovenOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05511623 | Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer | recruiting | Phase 2 | 112 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT04989647 | Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy(CERVANTES) | recruiting | Phase 3 | 514 | The Central and Eastern European Gynecologic Oncology GroupOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05378087 | Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer | recruiting | N/A | 1,956 | Chongqing University Cancer HospitalOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05709769 | Radiomics-based Malnutrition for Cervical Cancer. | recruiting | — | 150 | Zhejiang Provincial People's HospitalOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05937958 | MRLinac Boost for Gynecological Cancers if Brachytherapy is Not Feasible (MARGARITA)(MARGARITA) | recruiting | — | 30 | UMC UtrechtOTHER | 2 | Jul 18, 2023 | clinicaltrials |
| NCT05950087 | Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy | recruiting | — | 30 | Guizhou Provincial People's HospitalOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05945407 | Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer | recruiting | N/A | 57 | Peking University People's HospitalOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04370496 | Safety of Minimally Invasive Surgery Using Endoscopic Stapler in Early Stage Cervical Cancer Patients (SOLUTION)(SOLUTION) | recruiting | N/A | 124 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05912972 | Development and Management of Registry in Patients With Gynecologic Cancer in Korea | recruiting | — | 13,500 | Asan Medical CenterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05872724 | Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease) | recruiting | Phase 2 | 32 | Suzhou Municipal HospitalOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT04583254 | Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study | recruiting | Phase 2 | 48 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05808933 | Magnetic Resonance Fingerprinting for Preoperative Evaluation of Lymphovascular Space Invasion in Early Stage Cervical Cancer(MARF-ESC) | recruiting | — | 150 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04409860 | The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer(CQGOG0102) | recruiting | N/A | 120 | Chongqing University Cancer HospitalOTHER | 1 | Apr 11, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Apr 24, 2024source: clinicaltrials